<p>H.C. Wainwright 的分析师 Matthew Caufield 重申了对 LENZ Therapeutics 的买入评级，并将目标价格保持在 56.00 美元。</p>
<h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Matthew Caufield 给予买入评级是基于围绕 LENZ Therapeutics 的多种因素。尽管最近在 FDA 数据库中报告了一起不利事件，涉及一名在使用 VIZZ 老花眼滴眼液后出现视网膜撕裂的患者，但 Caufield 认为这一事件并不代表更广泛的风险。该患者有视网膜问题的历史，并且在开始治疗前没有进行推荐的视网膜检查，而这对于识别潜在风险至关重要。</p>
<p>Caufield 强调，市场的反应导致 LENZ 股票大幅下跌，实际上是对这一孤立事件的过度反应。他对在适当患者筛查下按预期使用该产品的安全性保持信心。买入评级的支持来自于对 VIZZ 初始推出阶段将获得关注的信念，特别是针对熟悉类似产品的开处方者的商业策略。Caufield 预计，只要开处方者遵循患者选择的指导方针并管理期望，该产品将在市场上成功被接受。</p>
<p>Caufield 关注医疗保健行业，重点关注 Immunic、LENZ Therapeutics 和 Opus Genetics 等股票。根据 TipRanks，Caufield 推荐股票的平均回报率为 21.6%，成功率为 47.16%。</p>
<p>在 12 月 4 日发布的另一份报告中，花旗也对该股票维持了买入评级，目标价格为 52.00 美元。</p>

LENZ

<p>H.C. Wainwright 的分析师 Matthew Caufield 重申了对 LENZ Therapeutics 的买入评级，维持 56 美元的目标价。尽管报告中提到 VIZZ 眼药水出现不良事件，Caufield 认为这是由于患者先前存在的视网膜问题而导致的个案。他认为市场对这一事件反应过度。Caufield 对产品在适当的患者筛选下的安全性充满信心，并预计市场将成功接受该产品。花旗也维持了买入评级，目标价为 52 美元</p>

<p>Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on LENZ Therapeutics and keeping the price target at $56.00.</p>
<div class="lb-trans"><p>H.C. Wainwright 的分析师 Matthew Caufield 重申了对 LENZ Therapeutics 的买入评级，并将目标价格保持在 56.00 美元。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Matthew Caufield has given his Buy rating due to a combination of factors surrounding LENZ Therapeutics. Despite a recent adverse event reported in the FDA’s database involving a patient with a retinal tear after using VIZZ presbyopia eye drops, Caufield believes this incident is not indicative of a broader risk. The patient in question had a history of retinal issues and did not undergo the recommended retinal examination before starting the therapy, which is crucial for identifying potential risks.</p>
<div class="lb-trans"><p>Matthew Caufield 给予买入评级是基于围绕 LENZ Therapeutics 的多种因素。尽管最近在 FDA 数据库中报告了一起不利事件，涉及一名在使用 VIZZ 老花眼滴眼液后出现视网膜撕裂的患者，但 Caufield 认为这一事件并不代表更广泛的风险。该患者有视网膜问题的历史，并且在开始治疗前没有进行推荐的视网膜检查，而这对于识别潜在风险至关重要。</p>
</div><p>Caufield emphasizes that the market’s reaction, which saw LENZ’s stock drop significantly, is an overreaction to this isolated case. He maintains confidence in the product’s safety profile when used as intended, with proper patient screening. The Buy rating is supported by the belief that the initial launch phase of VIZZ will gain traction, especially with the targeted commercial strategy aimed at prescribers familiar with similar products. Caufield expects that as long as prescribers adhere to guidelines for patient selection and manage expectations, the product will see successful adoption in the market.</p>
<div class="lb-trans"><p>Caufield 强调，市场的反应导致 LENZ 股票大幅下跌，实际上是对这一孤立事件的过度反应。他对在适当患者筛查下按预期使用该产品的安全性保持信心。买入评级的支持来自于对 VIZZ 初始推出阶段将获得关注的信念，特别是针对熟悉类似产品的开处方者的商业策略。Caufield 预计，只要开处方者遵循患者选择的指导方针并管理期望，该产品将在市场上成功被接受。</p>
</div><p>Caufield covers the Healthcare sector, focusing on stocks such as Immunic, LENZ Therapeutics, and Opus Genetics. According to TipRanks, Caufield has an average return of 21.6% and a 47.16% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Caufield 关注医疗保健行业，重点关注 Immunic、LENZ Therapeutics 和 Opus Genetics 等股票。根据 TipRanks，Caufield 推荐股票的平均回报率为 21.6%，成功率为 47.16%。</p>
</div><p>In another report released on December 4, Citi also maintained a Buy rating on the stock with a $52.00 price target.</p>
<div class="lb-trans"><p>在 12 月 4 日发布的另一份报告中，花旗也对该股票维持了买入评级，目标价格为 52.00 美元。</p>
</div>

LENZ Therapeutics：尽管对单一不良事件反应过度，买入评级仍被确认